DE10028837A1 - Verfahren zum Nachweis von Influenza A/B-Viren - Google Patents
Verfahren zum Nachweis von Influenza A/B-VirenInfo
- Publication number
- DE10028837A1 DE10028837A1 DE10028837A DE10028837A DE10028837A1 DE 10028837 A1 DE10028837 A1 DE 10028837A1 DE 10028837 A DE10028837 A DE 10028837A DE 10028837 A DE10028837 A DE 10028837A DE 10028837 A1 DE10028837 A1 DE 10028837A1
- Authority
- DE
- Germany
- Prior art keywords
- influenza
- saliva
- detection
- virus
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003296 saliva Anatomy 0.000 title claims abstract description 86
- 208000037797 influenza A Diseases 0.000 title claims abstract description 62
- 241000712431 Influenza A virus Species 0.000 title claims abstract description 28
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 11
- 238000001514 detection method Methods 0.000 title claims description 72
- 108020004707 nucleic acids Proteins 0.000 title claims description 14
- 102000039446 nucleic acids Human genes 0.000 title claims description 14
- 150000007523 nucleic acids Chemical class 0.000 title claims description 14
- 102000011931 Nucleoproteins Human genes 0.000 title claims description 8
- 108010061100 Nucleoproteins Proteins 0.000 title claims description 8
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 title abstract description 5
- 238000004458 analytical method Methods 0.000 title description 2
- 238000012360 testing method Methods 0.000 claims abstract description 57
- 241000700605 Viruses Species 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 70
- 208000037798 influenza B Diseases 0.000 claims description 38
- 230000001900 immune effect Effects 0.000 claims description 22
- 241000713196 Influenza B virus Species 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 9
- 239000012139 lysis buffer Substances 0.000 claims description 6
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 206010022000 influenza Diseases 0.000 description 37
- 210000003800 pharynx Anatomy 0.000 description 32
- 241000712461 unidentified influenza virus Species 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000868182 Thermus thermophilus HB8 Species 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940071125 manganese acetate Drugs 0.000 description 1
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012129 rapid antigen test Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10028837A DE10028837A1 (de) | 2000-06-15 | 2000-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren |
| ES01956475.6T ES2298244T5 (es) | 2000-06-15 | 2001-06-15 | Método para la detección de los virus de la gripe A/B en saliva |
| PCT/EP2001/006735 WO2001096595A2 (de) | 2000-06-15 | 2001-06-15 | Verfahren zum nachweis von influenza a/b-viren aus speichel |
| DE50113548T DE50113548D1 (de) | 2000-06-15 | 2001-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren in Speichel |
| CA002412121A CA2412121C (en) | 2000-06-15 | 2001-06-15 | Method for the detection of influenza a/b viruses |
| JP2002510708A JP2004503248A (ja) | 2000-06-15 | 2001-06-15 | インフルエンザａウイルスおよび／またはインフルエンザｂウイルスの検出方法 |
| US10/311,523 US6811971B2 (en) | 2000-06-15 | 2001-06-15 | Method for the detection of influenza A/B viruses |
| AT01956475T ATE385259T1 (de) | 2000-06-15 | 2001-06-15 | Verfahren zum nachweis von influenza a/b-viren in speichel |
| AU2001278452A AU2001278452A1 (en) | 2000-06-15 | 2001-06-15 | Method for the detection of influenza a/b viruses |
| EP01956475.6A EP1297187B2 (de) | 2000-06-15 | 2001-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren in Speichel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10028837A DE10028837A1 (de) | 2000-06-15 | 2000-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10028837A1 true DE10028837A1 (de) | 2001-12-20 |
Family
ID=7645396
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10028837A Ceased DE10028837A1 (de) | 2000-06-15 | 2000-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren |
| DE50113548T Expired - Lifetime DE50113548D1 (de) | 2000-06-15 | 2001-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren in Speichel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50113548T Expired - Lifetime DE50113548D1 (de) | 2000-06-15 | 2001-06-15 | Verfahren zum Nachweis von Influenza A/B-Viren in Speichel |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6811971B2 (enExample) |
| EP (1) | EP1297187B2 (enExample) |
| JP (1) | JP2004503248A (enExample) |
| AT (1) | ATE385259T1 (enExample) |
| AU (1) | AU2001278452A1 (enExample) |
| CA (1) | CA2412121C (enExample) |
| DE (2) | DE10028837A1 (enExample) |
| ES (1) | ES2298244T5 (enExample) |
| WO (1) | WO2001096595A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057605A3 (en) * | 2006-11-10 | 2008-07-17 | Quidel Corp | Nuclear protein extraction medium and method of use |
| WO2009142742A1 (en) * | 2008-05-20 | 2009-11-26 | Cantimer, Inc. | Methods, systems and devices for analyzing a biological fluid sample following ion exchange |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004028342A2 (en) * | 2002-09-25 | 2004-04-08 | Board Of Regents, The University Of Texas System | Endogenous granzyme b in human non-hematopoietic cells |
| AU2006244460B2 (en) * | 2005-05-06 | 2010-04-08 | Gen-Probe Incorporated | Compositions and assays to detect influenza virus A and B nucleic acids |
| WO2007098184A2 (en) * | 2006-02-21 | 2007-08-30 | Nanogen, Inc. | Methods and compositions for analyte detection |
| US20080208486A1 (en) * | 2006-03-23 | 2008-08-28 | Jari Natunen | Integrated System, Device and Use Thereof |
| US20070238095A1 (en) * | 2006-04-11 | 2007-10-11 | Mayo Foundation For Medical Education And Research , A Minnesota Corporation | Detection of Influenza A Virus |
| US20070238093A1 (en) * | 2006-04-11 | 2007-10-11 | Espy Mark J | Detection of influenza A virus |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US20090098527A1 (en) * | 2006-09-12 | 2009-04-16 | Fischer Gerald W | Biological organism identification product and methods |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| FI20060946A0 (fi) * | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
| CA2684213A1 (en) | 2007-04-12 | 2008-10-23 | Regents Of The University Of Minnesota | Ischemia/reperfusion protection compositions and methods of using |
| EP2174957B1 (en) | 2007-06-15 | 2016-03-16 | Xiamen University | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| EP3058954B1 (en) | 2007-08-27 | 2017-03-01 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| ES2552858T3 (es) * | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| US20110046001A1 (en) * | 2007-11-20 | 2011-02-24 | Autogenomics, Inc. | Multiplex Assay for Respiratory Viruses |
| US8354230B2 (en) | 2007-12-21 | 2013-01-15 | Quest Diagnostics Investments Inc. | Multiplex detection assay for influenza and RSV viruses |
| US20110045458A1 (en) * | 2009-08-20 | 2011-02-24 | Mayo Foundation For Medical Education And Research | Detection of Enterovirus |
| KR101919330B1 (ko) * | 2011-06-16 | 2018-11-19 | 후지필름 가부시키가이샤 | 고감도의 면역크로마토그래프 방법 및 면역크로마토그래프용 키트 |
| EP3494989B1 (en) | 2012-01-26 | 2025-07-16 | Longhorn Vaccines and Diagnostics, LLC | Composite antigenic sequences and vaccines |
| CA2985652C (en) | 2015-05-14 | 2020-03-10 | Gerald W. FISHER | Rapid methods for the extraction of nucleic acids from biological samples |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| GB201703383D0 (en) | 2017-03-02 | 2017-04-19 | Gargle Tech Ltd | Testing for particulates |
| EP4205851A3 (en) | 2018-09-05 | 2023-10-04 | Hero Scientific Ltd | Testing for particulates |
| WO2020095584A1 (ja) * | 2018-11-08 | 2020-05-14 | パナソニックＩｐマネジメント株式会社 | 検出システム及び情報表示システム |
| WO2020116012A1 (ja) | 2018-12-04 | 2020-06-11 | 株式会社村田製作所 | ウイルス検出システム、ウイルス検出方法、及びウイルス検出プログラム |
| US11053531B2 (en) | 2019-05-31 | 2021-07-06 | Linda Marie Petter | Tester paper and methods of use thereof for detecting a bacterial infection |
| WO2021181339A1 (en) | 2020-03-11 | 2021-09-16 | Hero Scientific Ltd. | Testing devices |
| CA3202405A1 (en) | 2021-01-06 | 2022-07-14 | Zvi Feldman | Filtration sampling devices |
| US20240302370A1 (en) * | 2021-02-12 | 2024-09-12 | Siemens Healthcare Diagnostics Inc. | Sample lysis reagent compositions and methods of production and use thereof |
| US20240410910A1 (en) * | 2021-07-22 | 2024-12-12 | Assaya Llc | Machine testing quality verification |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2104683C (en) | 1990-12-31 | 2004-06-29 | Avraham Liav | Method for visually detecting the presence of a virus in a clinical specimen |
| FR2708348B1 (fr) | 1993-07-28 | 1995-10-06 | Stago Diagnostica | Procédé de dosage d'une substance immunologique au moyen de particules de latex magnétiques et de particules non-magnétiques. |
| US5714341A (en) | 1994-03-30 | 1998-02-03 | Epitope, Inc. | Saliva assay method and device |
| US6015664A (en) | 1995-11-03 | 2000-01-18 | Mcw Research Foundation | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
| EP1010981A1 (de) | 1998-12-18 | 2000-06-21 | Diagor GmbH | Konjugate zum Nachweis von Viren und deren Verwendung |
-
2000
- 2000-06-15 DE DE10028837A patent/DE10028837A1/de not_active Ceased
-
2001
- 2001-06-15 AU AU2001278452A patent/AU2001278452A1/en not_active Abandoned
- 2001-06-15 EP EP01956475.6A patent/EP1297187B2/de not_active Expired - Lifetime
- 2001-06-15 ES ES01956475.6T patent/ES2298244T5/es not_active Expired - Lifetime
- 2001-06-15 AT AT01956475T patent/ATE385259T1/de active
- 2001-06-15 CA CA002412121A patent/CA2412121C/en not_active Expired - Fee Related
- 2001-06-15 JP JP2002510708A patent/JP2004503248A/ja active Pending
- 2001-06-15 US US10/311,523 patent/US6811971B2/en not_active Expired - Lifetime
- 2001-06-15 DE DE50113548T patent/DE50113548D1/de not_active Expired - Lifetime
- 2001-06-15 WO PCT/EP2001/006735 patent/WO2001096595A2/de not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057605A3 (en) * | 2006-11-10 | 2008-07-17 | Quidel Corp | Nuclear protein extraction medium and method of use |
| WO2009142742A1 (en) * | 2008-05-20 | 2009-11-26 | Cantimer, Inc. | Methods, systems and devices for analyzing a biological fluid sample following ion exchange |
| US8426207B2 (en) | 2008-05-20 | 2013-04-23 | Cantimer, Inc. | Methods, systems and devices for analyzing a biological fluid sample following ion exchange |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50113548D1 (de) | 2008-03-20 |
| EP1297187B1 (de) | 2008-01-30 |
| US6811971B2 (en) | 2004-11-02 |
| ES2298244T3 (es) | 2008-05-16 |
| US20030143530A1 (en) | 2003-07-31 |
| WO2001096595A2 (de) | 2001-12-20 |
| ES2298244T5 (es) | 2014-11-14 |
| EP1297187B2 (de) | 2014-08-13 |
| AU2001278452A1 (en) | 2001-12-24 |
| ATE385259T1 (de) | 2008-02-15 |
| JP2004503248A (ja) | 2004-02-05 |
| WO2001096595A3 (de) | 2002-05-23 |
| CA2412121A1 (en) | 2002-12-09 |
| CA2412121C (en) | 2009-09-01 |
| EP1297187A2 (de) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1297187B1 (de) | Verfahren zum Nachweis von Influenza A/B-Viren in Speichel | |
| Suleman et al. | Point of care detection of COVID-19: Advancement in biosensing and diagnostic methods | |
| Dronina et al. | Advances and insights in the diagnosis of viral infections | |
| Smith et al. | The incidence of Herpesvirus hominis antibody in the population | |
| World Health Organization | WHO manual on animal influenza diagnosis and surveillance | |
| Rota et al. | Detection of measles virus RNA in urine specimens from vaccine recipients | |
| DE3882705T2 (de) | Immunoglobulin-bestimmungsverfahren. | |
| Spira et al. | Micromethod for assaying reverse transcriptase of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus | |
| Lohr et al. | Detection of cytomegalovirus nucleic acid sequences in pancreas in type 2 diabetes | |
| DE202020105116U1 (de) | Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion | |
| CN102337351A (zh) | 一种流感病毒分型检测试剂盒 | |
| DE69008743T2 (de) | Extraktionszusammensetzung, Testsatz und deren Verwendung zum Nachweis von Herpes-Simplex-Antigen. | |
| JP5198710B2 (ja) | 免疫学的測定方法 | |
| EP0769954B1 (de) | Qualitätsgesichertes arzneimittel, enthaltend ein oder mehrere plasmaderivate | |
| Henriques et al. | Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors | |
| DE2840847A1 (de) | Verfahren zum nachweis und zur bestimmung komplementbindender antikoerper | |
| DE3854834T2 (de) | Immuntest unter Verwendung von Antigenen, produziert in heterologen Organismen | |
| Hegazy et al. | Comparative evaluation of some techniques used for the detection of rabies virus | |
| Leparc et al. | Search for poliovirus in specimens from patients with the post‐polio syndrome | |
| EP0707635A1 (de) | Verfahren zum direkten und biochemisch funktionellen nachweis von retroviren in biologischen proben | |
| DE102020209412B4 (de) | Mittel und Verfahren zur An- oder Abreicherung und zum Nachweis von Coronaviren | |
| Carlisle et al. | A multicentre study comparing post-mortem SARS-CoV-2 antibody testing in Cape Town mortuaries | |
| EP0800084A1 (de) | Technik zum Nachweis von Infektionen mit dem TBE-Virus und anderen Flaviviren | |
| DE60211829T2 (de) | Nachweis von Variola Virus | |
| DE60304336T2 (de) | Serologisches in-vitro-verfahren zur diagnose von infektiöser endokarditis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8131 | Rejection |